Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 297

1.

Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state.

den Hollander J, Rimpi S, Doherty JR, Rudelius M, Buck A, Hoellein A, Kremer M, Graf N, Scheerer M, Hall MA, Goga A, von Bubnoff N, Duyster J, Peschel C, Cleveland JL, Nilsson JA, Keller U.

Blood. 2010 Sep 2;116(9):1498-505. doi: 10.1182/blood-2009-11-251074. Epub 2010 Jun 2.

2.

Aurora kinase targeting in lung cancer reduces KRAS-induced transformation.

Dos Santos EO, Carneiro-Lobo TC, Aoki MN, Levantini E, Bassères DS.

Mol Cancer. 2016 Feb 3;15:12. doi: 10.1186/s12943-016-0494-6.

3.

Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target.

Hartsink-Segers SA, Zwaan CM, Exalto C, Luijendijk MW, Calvert VS, Petricoin EF, Evans WE, Reinhardt D, de Haas V, Hedtjärn M, Hansen BR, Koch T, Caron HN, Pieters R, Den Boer ML.

Leukemia. 2013 Mar;27(3):560-8. doi: 10.1038/leu.2012.256. Epub 2012 Sep 3.

4.

Daurinol Enhances the Efficacy of Radiotherapy in Lung Cancer via Suppression of Aurora Kinase A/B Expression.

Woo JK, Kang JH, Shin D, Park SH, Kang K, Nho CW, Seong JK, Lee SJ, Oh SH.

Mol Cancer Ther. 2015 Jul;14(7):1693-704. doi: 10.1158/1535-7163.MCT-14-0960. Epub 2015 Apr 16.

5.

The IKK2/NF-{kappa}B pathway suppresses MYC-induced lymphomagenesis.

Klapproth K, Sander S, Marinkovic D, Baumann B, Wirth T.

Blood. 2009 Sep 17;114(12):2448-58. doi: 10.1182/blood-2008-09-181008. Epub 2009 Jul 23.

6.

The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomas.

Forshell LP, Li Y, Forshell TZ, Rudelius M, Nilsson L, Keller U, Nilsson J.

Oncotarget. 2011 Jun;2(6):448-60.

7.

BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia.

Ott CJ, Kopp N, Bird L, Paranal RM, Qi J, Bowman T, Rodig SJ, Kung AL, Bradner JE, Weinstock DM.

Blood. 2012 Oct 4;120(14):2843-52. doi: 10.1182/blood-2012-02-413021. Epub 2012 Aug 17.

8.

Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma.

Mazumdar A, Henderson YC, El-Naggar AK, Sen S, Clayman GL.

Head Neck. 2009 May;31(5):625-34. doi: 10.1002/hed.21007.

9.

An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735.

Hook KE, Garza SJ, Lira ME, Ching KA, Lee NV, Cao J, Yuan J, Ye J, Ozeck M, Shi ST, Zheng X, Rejto PA, Kan JL, Christensen JG, Pavlicek A.

Mol Cancer Ther. 2012 Mar;11(3):710-9. doi: 10.1158/1535-7163.MCT-11-0184. Epub 2012 Jan 5.

10.

Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase.

Yang D, Liu H, Goga A, Kim S, Yuneva M, Bishop JM.

Proc Natl Acad Sci U S A. 2010 Aug 3;107(31):13836-41. doi: 10.1073/pnas.1008366107. Epub 2010 Jul 19.

11.

Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas.

Zappasodi R, Cavanè A, Iorio MV, Tortoreto M, Guarnotta C, Ruggiero G, Piovan C, Magni M, Zaffaroni N, Tagliabue E, Croce CM, Zunino F, Gianni AM, Di Nicola M.

Int J Cancer. 2014 Nov 1;135(9):2034-45. doi: 10.1002/ijc.28852. Epub 2014 Mar 26.

13.

Identification of Myc-associated protein with JmjC domain as a novel therapeutic target oncogene for lung cancer.

Suzuki C, Takahashi K, Hayama S, Ishikawa N, Kato T, Ito T, Tsuchiya E, Nakamura Y, Daigo Y.

Mol Cancer Ther. 2007 Feb;6(2):542-51.

14.

MicroRNA-146a modulates B-cell oncogenesis by regulating Egr1.

Contreras JR, Palanichamy JK, Tran TM, Fernando TR, Rodriguez-Malave NI, Goswami N, Arboleda VA, Casero D, Rao DS.

Oncotarget. 2015 May 10;6(13):11023-37.

15.

The feed-forward loop between YB-1 and MYC is essential for multiple myeloma cell survival.

Bommert KS, Effenberger M, Leich E, Küspert M, Murphy D, Langer C, Moll R, Janz S, Mottok A, Weissbach S, Rosenwald A, Bargou R, Bommert K.

Leukemia. 2013 Feb;27(2):441-50. doi: 10.1038/leu.2012.185. Epub 2012 Jul 9.

16.

STK38 is a critical upstream regulator of MYC's oncogenic activity in human B-cell lymphoma.

Bisikirska BC, Adam SJ, Alvarez MJ, Rajbhandari P, Cox R, Lefebvre C, Wang K, Rieckhof GE, Felsher DW, Califano A.

Oncogene. 2013 Nov 7;32(45):5283-91. doi: 10.1038/onc.2012.543. Epub 2012 Nov 26.

17.

Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis.

Sabò A, Kress TR, Pelizzola M, de Pretis S, Gorski MM, Tesi A, Morelli MJ, Bora P, Doni M, Verrecchia A, Tonelli C, Fagà G, Bianchi V, Ronchi A, Low D, Müller H, Guccione E, Campaner S, Amati B.

Nature. 2014 Jul 24;511(7510):488-492. doi: 10.1038/nature13537. Epub 2014 Jul 9.

18.

Identification of aurora kinase B and Wee1-like protein kinase as downstream targets of (V600E)B-RAF in melanoma.

Sharma A, Madhunapantula SV, Gowda R, Berg A, Neves RI, Robertson GP.

Am J Pathol. 2013 Apr;182(4):1151-62. doi: 10.1016/j.ajpath.2012.12.019. Epub 2013 Feb 12.

19.

Aurora kinase A mediates c-Myc's oncogenic effects in hepatocellular carcinoma.

Lu L, Han H, Tian Y, Li W, Zhang J, Feng M, Li Y.

Mol Carcinog. 2015 Nov;54(11):1467-79. doi: 10.1002/mc.22223. Epub 2014 Oct 4.

PMID:
25284017
20.

AKT signalling is required for ribosomal RNA synthesis and progression of Eμ-Myc B-cell lymphoma in vivo.

Devlin JR, Hannan KM, Ng PY, Bywater MJ, Shortt J, Cullinane C, McArthur GA, Johnstone RW, Hannan RD, Pearson RB.

FEBS J. 2013 Nov;280(21):5307-16. doi: 10.1111/febs.12135. Epub 2013 Feb 13.

Supplemental Content

Support Center